



2016/2057(INI)

7.9.2016

AMENDMENTS

1 - 85

Draft opinion

Joëlle Mélin

(PE582.446v01-00)

EU options for improving access to medicines

(2016/2057(INI))

Amendment 1
Heinz K. Becker

Draft opinion
Recital A

Draft opinion

Amendment

A. *whereas guaranteeing universal access to medicines presents a myriad of challenges;*

deleted

Or. de

Amendment 2
Lynn Boylan

Draft opinion
Recital A

Draft opinion

Amendment

A. *whereas guaranteeing universal access to medicines presents a myriad of challenges;*

deleted

Or. en

Amendment 3
Marian Harkin

Draft opinion
Recital A

Draft opinion

Amendment

A. *whereas guaranteeing universal access to medicines presents a **myriad of challenges;***

A. *whereas guaranteeing universal access to medicines presents a **many challenges but nonetheless must be our common goal;***

Or. en

Amendment 4
Notis Marias

Draft opinion
Recital A

Draft opinion

A. whereas **guaranteeing** universal access to medicines **presents a myriad of challenges**;

Amendment

A. whereas universal access to medicines **is an infeasible right**;

Or. el

Amendment 5
Enrico Gasbarra

Draft opinion
Recital A

Draft opinion

A. whereas guaranteeing universal access to medicines presents a myriad of challenges;

Amendment

A. whereas guaranteeing universal access to medicines presents a myriad of **pressing** challenges **which must have priority**;

Or. it

Amendment 6
Eleftherios Synadinos

Draft opinion
Recital A

Draft opinion

A. whereas guaranteeing universal access to medicines presents a myriad of challenges;

Amendment

A. whereas guaranteeing universal access to medicines presents a myriad of challenges; **whereas Article 34 (social security and social assistance) of the Charter of Fundamental Rights of the European Union categorically prohibits exclusion from access to medicines**;

Amendment 7
Lynn Boylan

Draft opinion
Recital A a (new)

Draft opinion

Amendment

Aa. Calls for universal access to quality healthcare in Member States; believes this to be a fundamental right of European citizens; further believes this to be the only way to ensure equality in healthcare for citizens in all European Union Member States.

Or. en

Amendment 8
Marian Harkin

Draft opinion
Recital B

Draft opinion

Amendment

B. whereas people living with disabilities are the most vulnerable and need medicines the most;

deleted

Or. en

Amendment 9
Lynn Boylan

Draft opinion
Recital B

Draft opinion

Amendment

B. whereas people living with

B. whereas people living with

disabilities are the most vulnerable and need medicines the most;

disabilities, *as well as those with long term illnesses that are not life threatening but do hamper and hinder quality of life and make everyday living more difficult than for a person in full health*, are the most vulnerable and need medicines the most;

Or. en

Amendment 10
Helga Stevens

Draft opinion
Recital B

Draft opinion

B. whereas people living with disabilities *are the most vulnerable and need medicines the most*;

Amendment

B. whereas people living with disabilities *for which there is no treatment/drug yet or people living with rare disabilities are in a particularly parlous position*;

Or. nl

Amendment 11
Notis Marias

Draft opinion
Recital B

Draft opinion

B. whereas people living with disabilities are the most vulnerable and need medicines *the most*;

Amendment

B. whereas people living with disabilities are the most vulnerable and *are in great need of* medicines;

Or. el

Amendment 12
Sofia Ribeiro

Draft opinion
Recital B

Draft opinion

B. whereas *people living with disabilities* are the most vulnerable *and need medicines the most*;

Amendment

B. whereas *it is those who* are the most vulnerable *that have the greatest difficulty in accessing medicines*;

Or. pt

Amendment 13
Heinz K. Becker

Draft opinion
Recital C

Draft opinion

C. *whereas the EU will need to oversee improvements in a range of fields that have an impact on how medicines are produced and distributed*;

Amendment

deleted

Or. de

Amendment 14
Notis Marias

Draft opinion
Recital C

Draft opinion

C. *whereas EU decisions will be conditioned by measures to achieve improvements in a range of fields that have an impact on how medicines are produced and distributed*;

Amendment

deleted

Or. el

Amendment 15
Marian Harkin

Draft opinion
Recital C

Draft opinion

C. whereas the EU will need to oversee improvements in a range of fields that have an impact on how medicines are produced and distributed;

Amendment

C. whereas the EU will need to oversee improvements in a range of fields that have an impact on how medicines are produced and distributed ***as well as ensuring the right of patients to all relevant information;***

Or. en

Amendment 16
Lynn Boylan

Draft opinion
Recital C

Draft opinion

C. whereas the EU will need to oversee improvements in a range of fields that have an impact on how medicines are produced and distributed;

Amendment

C. whereas the EU will need to oversee improvements in a range of fields that have an impact on how medicines are produced and distributed; ***calls on the Member States to support research and development (R&D) that focuses on the medical needs of all citizens, through ensuring that the structure for funding the research, development and commercialisation of new medicines is redirected towards the public good and to guarantee affordable and non-discriminatory access to medical advances, examining options such as bulk buying, risk sharing, and state funding of R&D; also calls on Member States to particularly focus on R&D to tackle antimicrobial resistance;***

Or. en

Amendment 17
Helga Stevens

Draft opinion
Recital C a (new)

Draft opinion

Amendment

Ca. whereas the Member States all have different basic set-ups for their social security systems and for funding them, and whereas this opinion has no bearing on them;

Or. nl

Amendment 18
Helga Stevens

Draft opinion
Recital C b (new)

Draft opinion

Amendment

Cb. whereas access to drugs, under certain conditions, can be considered to be of general economic interest within the meaning of Article 106(2) TFEU; whereas Treaty rules, in particular competition rules, can accordingly be disapplied in so far as is necessary to achieve the objective pursued;

Or. nl

Amendment 19
Yana Toom, Ilhan Kyuchyuk

Draft opinion
Paragraph 1

Draft opinion

Amendment

1. Stresses the importance *of observing the principle of subsidiarity, as*

1. Stresses the importance *for each Member State to ensure accessibility of*

each Member State must address any shortcomings on the basis of its own particular requirements;

pharmacies, including their density in both urban and rural areas, professional staff number, appropriate opening hours, qualitative advice and counselling service;

Or. en

Amendment 20
Helga Stevens

Draft opinion
Paragraph 1

Draft opinion

1. Stresses the importance of observing the principle of subsidiarity, *as each Member State must address any shortcomings on the basis of its own particular requirements;*

Amendment

1. Stresses the importance of observing the principle of subsidiarity; *takes the view, however, that better access to medicines can be achieved through better cooperation between Member States;*

Or. nl

Amendment 21
Enrico Gasbarra

Draft opinion
Paragraph 1

Draft opinion

1. Stresses *the importance of observing* the principle of subsidiarity, *as each Member State must* address any shortcomings on the basis of its own particular requirements;

Amendment

1. Stresses *how important it is that, in keeping with* the principle of subsidiarity, each Member State *should* address any shortcomings on the basis of its own particular requirements, *by optimising the targeting and use of the instruments at its disposal and seeking - above all as regards drugs used to treat rare diseases - to reduce the current substantial differences in cost;*

Or. it

Amendment 22
Notis Marias

Draft opinion
Paragraph 1

Draft opinion

1. Stresses the importance of observing the principle of subsidiarity, as each Member State must address any shortcomings on the basis of its own particular requirements;

Amendment

1. Stresses the importance of observing the principle of subsidiarity ***and proportionality***, as each Member State must address any shortcomings on the basis of its own particular requirements; ***points out that the financial adjustments arbitrarily imposed by the Troika in the Memorandum countries, especially Greece, are making it impossible to address these shortcomings since, as a result of health cuts, medicines are now in woefully short supply;***

Or. el

Amendment 23
Eleftherios Synadinos

Draft opinion
Paragraph 1

Draft opinion

1. Stresses the importance of observing the principle of subsidiarity, as each Member State must address any shortcomings on the basis of its own particular requirements;

Amendment

1. Stresses the importance of observing the principle of subsidiarity, as each Member State must address any shortcomings on the basis of its own particular requirements, ***strictly adhering to the terms of Article 35 (health care) of the Charter of Fundamental Rights of the EU, regardless of financial indicators;***

Or. el

Amendment 24
Heinz K. Becker

Draft opinion
Paragraph 1

Draft opinion

1. Stresses *the importance of observing the principle of subsidiarity*, as each Member State must *address* any shortcomings on the basis of its own particular requirements;

Amendment

1. Stresses *that* each Member State must *ensure that it addresses* any shortcomings on the basis of its own particular requirements;

Or. de

Amendment 25
Sofia Ribeiro

Draft opinion
Paragraph 1

Draft opinion

1. Stresses the importance of observing the principle of subsidiarity, as each Member State must address any shortcomings on the basis of its own particular requirements;

Amendment

1. Stresses the importance of observing the principle of subsidiarity, as each Member State must *manage its own resources and* address any shortcomings on the basis of its own particular requirements;

Or. pt

Amendment 26
Laura Agea, Tiziana Beghin, Daniela Aiuto, Piernicola Pedicini

Draft opinion
Paragraph 1 a (new)

Draft opinion

Amendment

1a. Regards universal access to medicines as essential, all the more so because the economic crisis in Europe has made such access even more of a

problem, in particular for the most vulnerable groups in society; urges, therefore, that these groups should be guaranteed access to medicines;

Or. it

Amendment 27
Arne Gericke

Draft opinion
Paragraph 1 a (new)

Draft opinion

Amendment

1a. Looks to the Member States to establish arrangements making use of the EU internal market with regard to medicines, too, and facilitating patient access throughout Europe to equivalent and, in all cases, the most cost-effective medicines;

Or. de

Amendment 28
Helga Stevens

Draft opinion
Paragraph 1 a (new)

Draft opinion

Amendment

1a. Calls for EU incentives so as to prompt governments to negotiate jointly with pharmaceuticals - instead of each going it alone - in order to arrive at better prices;

Or. nl

Amendment 29
Lynn Boylan

**Draft opinion
Paragraph 2**

Draft opinion

2. *Calls for support for the progress achieved by the pharmaceutical industry, hitherto driven by European SMEs, which have transformed the standard of healthcare in Europe and helped to prolong life expectancy;*

Amendment

deleted

Or. en

**Amendment 30
Romana Tomc**

**Draft opinion
Paragraph 2**

Draft opinion

2. *Calls for support for the progress achieved by the pharmaceutical industry, hitherto driven by European SMEs, which have transformed the standard of healthcare in Europe and helped to prolong life expectancy;*

Amendment

2. *Stresses the importance of SMEs in transforming the standard of healthcare in Europe and calls for further support for their development;*

Or. sl

**Amendment 31
Heinz K. Becker**

**Draft opinion
Paragraph 2**

Draft opinion

2. *Calls for support for the progress achieved by the pharmaceutical industry, hitherto driven by European SMEs, which have transformed the standard of healthcare in Europe and helped to*

Amendment

2. *Calls for backing to be given to European research projects and SMEs in order to improve the supply of essential medicines in Europe;*

prolong life expectancy;

Or. de

Amendment 32
Enrico Gasbarra

Draft opinion
Paragraph 2

Draft opinion

2. Calls for support for the progress achieved by the pharmaceutical industry, hitherto driven by European SMEs, which have transformed the standard of healthcare in Europe and helped to prolong life expectancy;

Amendment

2. Calls for support for the **research carried out and the** progress achieved by the pharmaceutical industry, hitherto driven by European SMEs, which have transformed the standard of healthcare in Europe and helped to prolong life expectancy;

Or. it

Amendment 33
Sofia Ribeiro

Draft opinion
Paragraph 2

Draft opinion

2. Calls for support for the progress achieved by the pharmaceutical industry, hitherto driven by European SMEs, which have transformed the standard of healthcare in Europe and helped to prolong life expectancy;

Amendment

2. Calls for support for the progress achieved by the pharmaceutical industry, **especially the progress** hitherto driven by European SMEs, which have transformed the standard of healthcare in Europe and helped to prolong life expectancy;

Or. pt

Amendment 34
Helga Stevens

Draft opinion
Paragraph 2

Draft opinion

2. Calls for support for the progress achieved by the pharmaceutical industry, hitherto driven by European SMEs, which have transformed the standard of healthcare in Europe and helped to prolong life expectancy;

Amendment

2. Calls for support for the progress achieved by the pharmaceutical industry, hitherto driven by European SMEs *too*, which have transformed the standard of healthcare in Europe and helped to prolong life expectancy;

Or. nl

Amendment 35
Notis Marias

Draft opinion
Paragraph 2

Draft opinion

2. Calls for support for the progress achieved by the pharmaceutical industry, hitherto driven by European SMEs, which have transformed the standard of healthcare in Europe and helped to prolong life expectancy;

Amendment

2. Calls for support for the progress achieved by the pharmaceutical industry, hitherto driven by European SMEs, which have transformed the standard of healthcare in Europe and helped to prolong life expectancy *by increasing EU funding for health services in the Member States*;

Or. el

Amendment 36
Lynn Boylan

Draft opinion
Paragraph 2 a (new)

Draft opinion

Amendment

2a. Deplores the fact that there are 18 million people across the EU without access to health care; finds it unacceptable that there are 25 000 annual deaths in the EU due to lack of effective

antibiotics; also finds it alarming that in a period of prosperity with many advances in healthcare, medicines and technology, there appears to be very little advancement in creating sustainable solutions for those without healthcare or medicines;

Or. en

Amendment 37
Yana Toom, Ilhan Kyuchyuk

Draft opinion
Paragraph 2 a (new)

Draft opinion

Amendment

2a. Emphasises that for the protection of health and life and in the interests of consumer protection information notes accompanying medicines might be provided by retailers in widely used languages of a particular Member State in addition to official language or languages;

Or. en

Amendment 38
Arne Gericke

Draft opinion
Paragraph 2 a (new)

Draft opinion

Amendment

2a. Stresses the need for access to suitable medicines for children and young people and for research and development in this connection;

Or. de

Amendment 39
Romana Tomc

Draft opinion
Paragraph 2 a (new)

Draft opinion

Amendment

2a. Stresses that everyone should have access to medicines, regardless of their social position;

Or. sl

Amendment 40
Sofia Ribeiro

Draft opinion
Paragraph 3

Draft opinion

Amendment

3. Recommends that each Member State should be free to set its own innovation policy in the field of cutting-edge technologies, possibly with the aid of EU funding;

deleted

Or. pt

Amendment 41
Heinz K. Becker

Draft opinion
Paragraph 3

Draft opinion

Amendment

3. Recommends that each Member State should be free to set its own innovation policy in the field of cutting-edge technologies, possibly with the aid of EU funding;

deleted

Or. de

Amendment 42
Romana Tomc

Draft opinion
Paragraph 3

Draft opinion

3. *Recommends that each Member State should be free to set its own innovation policy in the field of cutting-edge technologies, possibly with the aid of EU funding;*

Amendment

3. *Stresses that healthy competition should also be guaranteed in the area of access to medicines, so as to make possible lower prices and higher quality of services for users;*

Or. sl

Amendment 43
Helga Stevens

Draft opinion
Paragraph 3

Draft opinion

3. *Recommends that each Member State should be free to set its own innovation policy in the field of cutting-edge technologies, possibly with the aid of EU funding;*

Amendment

3. *Points out that innovation policy is conducted at Member State level; underlines the importance nonetheless of the EU's supportive and coordinating role; strongly believes that international cooperation and information sharing should be encouraged;*

Or. nl

Amendment 44
Marian Harkin

Draft opinion
Paragraph 3

Draft opinion

3. *Recommends that each Member State should be free to set its own innovation policy in the field of cutting-*

Amendment

3. *Believes that co-operation between Member States along with the sharing of expertise, leads to greater synergy in the*

edge technologies, possibly with the aid of EU funding;

field of *innovation policy and recognises the importance* of EU funding *in supporting such initiatives*;

Or. en

Amendment 45
Enrico Gasbarra

Draft opinion
Paragraph 3

Draft opinion

3. Recommends that each Member State should be free to set its own innovation policy in the field of cutting-edge technologies, *possibly* with the aid of EU funding;

Amendment

3. Recommends that each Member State should be free to *invest and* set its own innovation policy in the field of cutting-edge technologies *for disease prevention and public health and well-being, in part* with the aid of EU funding;

Or. it

Amendment 46
Csaba Sógor

Draft opinion
Paragraph 3

Draft opinion

3. Recommends that each Member State should be *free* to set *its own innovation policy* in the field of *cutting-edge technologies, possibly with the aid of* EU funding;

Amendment

3. Recommends that each Member State should be *encouraged* to set *up innovation and cutting edge technology policies, including* in the field of *medicines, and to make the best use of available* EU funding *in this area*;

Or. en

Amendment 47
Notis Marias

Draft opinion
Paragraph 3

Draft opinion

3. Recommends that each Member State should be free to set its own innovation policy in the field of cutting-edge technologies, *possibly with the aid of* EU funding;

Amendment

3. Recommends that each Member State should be free to set its own innovation policy in the field of cutting-edge technologies *by stepping up* EU funding;

Or. el

Amendment 48
Yana Toom, Ilhan Kyuchyuk

Draft opinion
Paragraph 3

Draft opinion

3. Recommends that each Member State should *be free to set* its own innovation policy in the field of cutting-edge technologies, possibly with the aid of EU funding;

Amendment

3. Recommends that each Member State should *develop* its own innovation policy in the field of cutting-edge technologies, possibly with the aid of EU funding;

Or. en

Amendment 49
Helga Stevens

Draft opinion
Paragraph 3 a (new)

Draft opinion

Amendment

3a. Takes the view that the development of an international tool for assessing the efficiency/effectiveness of medicines would be a major advance; calls on the EU to promote the importance of scientific evidence that is freed of all political considerations;

Amendment 50

Laura Agea, Tiziana Beghin, Daniela Aiuto, Piernicola Pedicini

Draft opinion

Paragraph 3 a (new)

Draft opinion

Amendment

3a. Urges that access to medicines should be guaranteed for people in all countries, not just in those with effective innovation policies; points out that innovation does not always serve to ensure that medicines are more readily available, and indeed may have the opposite effect;

Or. it

Amendment 51

Marian Harkin

Draft opinion

Paragraph 3 a (new)

Draft opinion

Amendment

3a. Recommends that EU health research programmes should ensure greater knowledge sharing and that the rules for participating in EU research programmes could include possible mandatory conditions for licencing that preserve public policy objectives;

Or. en

Amendment 52

Enrico Gasbarra

Draft opinion
Paragraph 4

Draft opinion

4. Recommends that information sharing **and** the training of medical professionals be made an immediate priority;

Amendment

4. Recommends that information sharing, the training of medical professionals **and exchanges of best practice** be made an immediate priority **with a view to bringing about a gradual but decisive improvement in the provision of healthcare, and emphasises that the development of the instruments which new technologies are now making available in the areas of research, ease of access to patients, also in their own homes, and the sharing of information could play a key role in facilitating the provision of healthcare;**

Or. it

Amendment 53
Helga Stevens

Draft opinion
Paragraph 4

Draft opinion

4. **Recommends** that information sharing and **the training of** medical professionals **be made** an immediate priority;

Amendment

4. **Points out** that information sharing and **high-quality training for** medical professionals **is** an immediate priority; **stresses that it is also very important to 'train' patients as regards prevention and get them to take that on board;**

Or. nl

Amendment 54
Heinz K. Becker

Draft opinion
Paragraph 4

Draft opinion

4. Recommends that information sharing and *the* training *of* medical professionals be made an immediate priority;

Amendment

4. Recommends that information sharing *at European level* and *high-quality* training *for* medical professionals be made an immediate priority;

Or. de

Amendment 55
Sofia Ribeiro

Draft opinion
Paragraph 4

Draft opinion

4. Recommends that information sharing and the training of medical professionals be made an immediate priority;

Amendment

4. Recommends that information sharing and the training of medical professionals *and researchers* be made an immediate priority;

Or. pt

Amendment 56
Eleftherios Synadinos

Draft opinion
Paragraph 4

Draft opinion

4. Recommends that information sharing and the training of medical professionals be made an immediate priority;

Amendment

4. Recommends that information sharing and the training of medical professionals be made an immediate priority, *particularly regarding the prevention of incurable diseases and cancer*;

Or. el

Amendment 57

Lynn Boylan

Draft opinion

Paragraph 4

Draft opinion

4. Recommends that information sharing and the training of medical professionals be made an immediate priority;

Amendment

4. Recommends that information sharing and the training of medical professionals be made an immediate priority; ***highlights the negative impact that Member States' austerity policies and budgetary cuts have had on citizens access to healthcare and access to medicines; condemns the situation which has been fostered in healthcare systems whereby the value of a life is equated to wealth, whereby those who are financially better off can get quicker and better treatment than those lesser off;***

Or. en

Amendment 58

Arne Gericke

Draft opinion

Paragraph 4 a (new)

Draft opinion

Amendment

4a. Stresses the importance of comprehensive medicines supply in rural areas, too, and the attendant need to maintain small-scale family-run or owner-managed pharmacies;

Or. de

Amendment 59

Enrico Gasbarra

Draft opinion

Paragraph 5

Draft opinion

5. Urges that universal access to medicines should not be contingent on price, which should reflect a fair balance between the cost of research, industry growth and the need for sustainable welfare systems;

Amendment

5. ***Points out that prevention, health and well-being are fundamental rights and key principles underpinning a social Europe; urges, therefore, that there should be no inequality or discrimination as regards innovation and the provision of healthcare and*** that universal access to medicines should not be contingent on price, which should reflect a fair balance between the cost of research, industry growth and the need for sustainable welfare systems;

Or. it

Amendment 60
Helga Stevens

Draft opinion
Paragraph 5

Draft opinion

5. ***Urges that universal access to medicines should not be contingent on price, which should reflect a fair balance*** between the cost of research, industry growth and ***the need for*** sustainable welfare systems;

Amendment

5. ***Stresses that a fair balance must be sought*** between the cost of research, industry growth and sustainable welfare systems;

Or. nl

Amendment 61
Heinz K. Becker

Draft opinion
Paragraph 5

Draft opinion

5. ***Urges that universal access to medicines should not be contingent on***

Amendment

5. ***Points out that the cost of*** medicines should reflect a balance between

price, which should reflect a *fair* balance between the cost of research, industry growth and the need for sustainable welfare systems;

the cost of research, industry growth and the need for sustainable welfare systems; ***urges that universal access to medicines should not be contingent on price;***

Or. de

Amendment 62
Notis Marias

Draft opinion
Paragraph 5

Draft opinion

5. ***Urges that*** universal access to medicines ***should not be contingent on price, which should reflect a fair balance between the cost of*** research, industry growth and the need for sustainable welfare systems;

Amendment

5. ***Calls for*** universal access to medicines ***and increased funding for investment in*** research, industry growth and the need for sustainable welfare systems;

Or. el

Amendment 63
Laura Agea, Tiziana Beghin, Daniela Aiuto, Piernicola Pedicini

Draft opinion
Paragraph 5

Draft opinion

5. Urges that universal access to medicines should not be contingent on price, which should reflect a fair balance between the cost of research, industry growth and the need for sustainable welfare systems;

Amendment

5. Urges that universal access to medicines should not be contingent on price, which should reflect a fair balance between the cost of research, industry growth and the need for sustainable welfare systems; ***urges that a balance should be maintained at all times between research, development and sustainability, with a view to combating the pharmaceutical oligopolies which determine the price of medicines, even when the prices in question are unsustainable for many health systems,***

and in so doing create vast areas in which people are denied access to medicines;

Or. it

Amendment 64

Lynn Boylan

Draft opinion

Paragraph 5

Draft opinion

5. Urges that universal access to medicines should not be contingent on price, which should reflect a fair balance between the cost of research, industry growth and the need for sustainable welfare systems;

Amendment

5. Urges that universal access to medicines should not be contingent on price, which should reflect a fair balance between the cost of research, industry growth and the need for sustainable welfare systems; *sees patent rights as an obstacle to access to medicines, and urges public policy makers to take definitive steps towards addressing issues arising around patent rights; calls for greater transparency in public procurement prices for medicines;*

Or. en

Amendment 65

Eleftherios Synadinos

Draft opinion

Paragraph 5

Draft opinion

5. Urges that universal access to medicines should not be contingent on price, which should reflect a fair balance between the cost of research, industry growth and the need for sustainable welfare systems;

Amendment

5. Urges that universal access to medicines should not be contingent on price, which should reflect a fair balance between the cost of research, industry growth and the need for sustainable welfare systems, *particularly where co-payments for medication are beyond the means of those insured;*

Amendment 66
Sofia Ribeiro

Draft opinion
Paragraph 5 a (new)

Draft opinion

Amendment

5a. Recommends that a medicine price negotiation mechanism be devised to ensure greater uniformity at EU level, especially in those cases where the cost of the labour is incompatible with Member States' welfare systems;

Or. pt

Amendment 67
Csaba Sógor

Draft opinion
Paragraph 6

Draft opinion

Amendment

6. Reiterates that the stability of European welfare systems, which are one of the cornerstones of EU cooperation and whose budgets differ greatly from one Member State to another, is contingent on people being in employment, and that high levels of unemployment are making it essential to find new means of funding welfare;

deleted

Or. en

Amendment 68
Sofia Ribeiro

Draft opinion
Paragraph 6

Draft opinion

6. *Reiterates that the stability of European welfare systems, which are one of the cornerstones of EU cooperation and whose budgets differ greatly from one Member State to another, is contingent on people being in employment, and that high levels of unemployment are making it essential to find new means of funding welfare;*

Amendment

deleted

Or. pt

Amendment 69
Helga Stevens

Draft opinion
Paragraph 6

Draft opinion

6. *Reiterates that the stability of European welfare systems, which are one of the cornerstones of EU cooperation and whose budgets differ greatly from one Member State to another, is contingent on people being in employment, and that high levels of unemployment are making it essential to find new means of funding welfare;*

Amendment

6. *Takes the view that welfare systems must not be contingent solely on people being in employment, but, rather, that they must be funded from other revenue sources;*

Or. nl

Amendment 70
Heinz K. Becker

Draft opinion
Paragraph 6

Draft opinion

6. Reiterates that the stability of European welfare systems, which are one of the cornerstones of EU cooperation **and whose budgets differ greatly from one Member State to another**, is contingent on people being in employment, and **that high levels of unemployment are making it essential to find new means of funding welfare**;

Amendment

6. Reiterates that the stability of European welfare systems, which are one of the cornerstones of EU cooperation, is **primarily** contingent on people being in employment, and **therefore calls for new ways and means to be found so as to be able to continue to fund welfare systems in Europe**;

Or. de

Amendment 71
Notis Marias

Draft opinion
Paragraph 6

Draft opinion

6. Reiterates that the **stability of European welfare systems, which are one of the cornerstones of EU cooperation and whose budgets differ greatly from one Member State to another**, is contingent on people being in employment, and that **high levels of unemployment are making it essential to find new means of funding welfare**;

Amendment

6. Reiterates that the stability of the welfare systems, **the very high levels of unemployment in the Member States of southern Europe, such as Greece, Portugal, Italy and Spain, are a reflection of the social inequalities that exist within the Union**;

Or. el

Amendment 72
Lynn Boylan

Draft opinion
Paragraph 6

Draft opinion

6. Reiterates that the stability of European welfare systems, which are one

Amendment

6. Reiterates that the stability of European welfare systems, which are one

of the cornerstones of EU cooperation and whose budgets differ greatly from one Member State to another, is contingent on people being in employment, and that high levels of unemployment are making it essential to find new means of funding welfare;

of the cornerstones of EU cooperation and whose budgets differ greatly from one Member State to another, is contingent on people being in employment, and that high levels of unemployment are making it essential to find new means of funding welfare; ***condemns the transforming of health as an inherent right for all people, to a market based commodity that is subject to cost and profiteering which creates a social divide by promoting differential treatment based on a patient's ability to pay;***

Or. en

Amendment 73
Helga Stevens

Draft opinion
Paragraph 7

Draft opinion

Amendment

7. *Reiterates that part of the reason why businesses are becoming less competitive and why welfare spending is so high is that EU rules – including rules on drug pricing – are too burdensome.*

deleted

Or. nl

Amendment 74
Notis Marias

Draft opinion
Paragraph 7

Draft opinion

Amendment

7. *Reiterates that part of the reason why businesses are becoming less competitive and why welfare spending is so high is that EU rules – including rules on drug pricing – are too burdensome.*

deleted

Or. el

Amendment 75
Sofia Ribeiro

Draft opinion
Paragraph 7

Draft opinion

Amendment

7. *Reiterates that part of the reason why businesses are becoming less competitive and why welfare spending is so high is that EU rules – including rules on drug pricing – are too burdensome.* **deleted**

Or. pt

Amendment 76
Heinz K. Becker

Draft opinion
Paragraph 7

Draft opinion

Amendment

7. *Reiterates that part of the reason why businesses are becoming less competitive and why welfare spending is so high is that EU rules – including rules on drug pricing – are too burdensome.* **deleted**

Or. de

Amendment 77
Yana Toom, Ilhan Kyuchyuk

Draft opinion
Paragraph 7

Draft opinion

Amendment

7. *Reiterates that part of the reason why businesses are becoming less competitive and why welfare spending is so high is that EU rules – including rules on drug pricing – are too burdensome.* **deleted**

Or. en

Amendment 78
Marian Harkin

Draft opinion
Paragraph 7

Draft opinion

Amendment

7. *Reiterates that part of the reason why businesses are becoming less competitive and why welfare spending is so high is that EU rules – including rules on drug pricing – are too burdensome.*

deleted

Or. en

Amendment 79
Lynn Boylan

Draft opinion
Paragraph 7

Draft opinion

Amendment

7. *Reiterates that part of the reason why businesses are becoming less competitive and why welfare spending is so high is that EU rules – including rules on drug pricing – are too burdensome.*

deleted

Or. en

Amendment 80
Csaba Sógor

Draft opinion
Paragraph 7

Draft opinion

Amendment

7. *Reiterates that part of the reason why businesses are becoming less competitive and why welfare spending is*

7. *Stresses the need for EU medicine market regulation to ensure a high degree of consumer safety and health protection,*

so high is that EU rules – including rules on drug pricing – are too burdensome.

to ensure intellectual property rights and, at the same time a healthy competition through the use of generic medicines.

Or. en

Amendment 81
Eleftherios Synadinos

Draft opinion
Paragraph 7

Draft opinion

7. Reiterates that part of the reason why businesses are becoming less competitive and why welfare spending is so high is that EU rules – including rules on drug pricing – are too burdensome.

Amendment

7. Reiterates that part of the reason why businesses are becoming less competitive and why welfare spending is so high is that EU rules – including rules on drug pricing – are too burdensome, *in addition to which, austerity and economic adjustment policies are causing increased unemployment and resulting in welfare cuts.*

Or. el

Amendment 82
Laura Agea, Tiziana Beghin, Daniela Aiuto, Piernicola Pedicini

Draft opinion
Paragraph 7

Draft opinion

7. Reiterates that part of the reason why businesses are becoming less competitive and why welfare spending is so high is that EU rules – including rules on drug pricing – are too burdensome.

Amendment

7. Reiterates that part of the reason why businesses are becoming less competitive and why welfare spending is so high is that EU rules – including rules on drug pricing – are too burdensome; *points out that price of most medicines is out of proportion to the cost of manufacturing them; emphasises, in that connection, that firms' competitive position should have no bearing on the final price of medicines;*

Or. it

Amendment 83

Laura Agea, Tiziana Beghin, Daniela Aiuto, Piernicola Pedicini

Draft opinion

Paragraph 7 a (new)

Draft opinion

Amendment

7a. Points out that it is the pharmaceutical industry which is pressing for the enforcement of the rules on patents and thus preventing the use of generic drugs, which are cheaper and could thus be made more widely available; calls for information and awareness-raising campaigns to encourage the use of generic drugs;

Or. it

Amendment 84

Marian Harkin

Draft opinion

Paragraph 7 a (new)

Draft opinion

Amendment

7a. Calls on the Commission to find solutions to bring unprofitable but medically necessary drugs in to production;

Or. en

Amendment 85

Marian Harkin

Draft opinion

Paragraph 7 b (new)

Draft opinion

Amendment

7b. Calls on the Commission to increase research for neglected diseases;

